Ireland· IE-PA-PA22584/002/001

Oxybuprocaine Agepha 4 mg/ml eye drops, solution

A oxybuprocaine product containing oxybuprocaine hydrochloride, registered in Ireland by AGEPHA Pharma s.r.o.. The same ATC class is registered in 11 of our 19 countries.

ATC S01HA02

Checked against HPRA (Ireland) on September 28, 2026

Informational only — not a medical device.

Compare price across countriesPer daily dose · free account Ask the assistant about oxybuprocaine hydrochlorideAnswers with sources · free account Check interactionsSeverity free · mechanism on Growth

Where it is registered

Oxybuprocaine is registered in 11 of 19 countries.

Countries holding a registration under ATC S01HA02 (oxybuprocaine), each read from that country’s own register.

This record: Ireland, from HPRA (Ireland)
7 of them publish a price we can compare per daily dose

Search oxybuprocaine products by name

Oxybuprocaine · ATC S01HA02

11 / 19 countries

Belgiumprice
Czechiaprice
Denmark
Finlandprice
Icelandprice
Ireland
Netherlands
Norwayprice
Polandprice
Switzerlandprice
United Kingdom

Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

HPRA (Ireland)

Active substance: Oxybuprocaine hydrochloride
Manufacturer: AGEPHA Pharma s.r.o.
Country: Ireland (IE)
ATC code: S01HA02
ATC class: Oxybuprocaine
Reimbursed: Not published by this register
Source register: HPRA (Ireland)
Last checked: September 28, 2026

Packs & prices · 1

ie_pa_number
PA22584/002/001

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

40 interactions on record for oxybuprocaine.

Graded by severity as the source publishes them — 40 moderate. Severity grades are free for everyone; mechanism and management come with Growth.

Severity for every pair — free, no plan needed
The source, licence and sync date on every record
Mechanism and what to do for each pair — Growth plan

Check oxybuprocaine against other medicines How interaction checks work

Oxybuprocaine · interactions on record

40 records

40 moderate

Most severe, free to view

MetoclopramideA03FA01moderate
SulfamethizoleB05CA04moderate
LidocaineC01BB01moderate
Glyceryl trinitrateC01DA02moderate

Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.

Mechanism and what to do, in the interaction check

Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Oxybuprocaine in 13 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All oxybuprocaine products

Authorised across Europe · EMA

The same active substance is authorised in 25 EEA countries. Names it is sold under:

Austria · Benoxinat Zur Anästhesie In Der Oto-Rhino-Laryngologie, Novain
Belgium · Minims Oxybuprocaine Chlorhydrate Bausch + Lomb Ireland Limited, Minims Oxybuprocaïnehydrochloride Bausch + Lomb Ireland Limited
Bulgaria · Бенокси
Czechia · Benoxi, Oxybuprocaine Olikla
Germany · Conjuncain® Edo®, Novesine
Denmark · Oftasen, Oxybuprocainhydrochlorid Agepha
Estonia · Novain
Spain · Oxibuprocaína Hidrocloruro Agepha
Finland · Minims, Obupro 4 Mg/Ml Silmätipat, Liuos
France · Cebesine, Chlorhydrate D’oxybuprocaine Thea
United Kingdom (Northern Ireland) · Oxybuprocaine Hydrochloride Alfa Intes
Croatia · Ophtesia
Hungary · Humacain, Oxybuprocaine Hydrochloride Agepha
Iceland · Novain
Italy · Benoxinato Cloridrato Intes, Novesina
Lithuania · Novain
Luxembourg · Conjuncain Edo, Minims
Latvia · Oxybuprocaine Hydrochloride Agepha 4 Mg/Ml
Netherlands · Minims, Monofree
Norway · Obupro, Oxibuprokain Minims Bausch + Lomb Ireland Limited
Poland · Novain, 4 Mg/Ml,
Portugal · Anestocil, Novain 4 Mg/Ml Colírio,
Romania · Benoxi, Oftacain
Sweden · Novain, Oxibuprokain Bausch & Lomb
Slovakia · Benoxi, Oxybuprocaine Olikla

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of HPRA (Ireland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload

GET /v1/drugs/09867936-330b-4407-a91b-afd25b741f5f
GET /v1/drugs/09867936-330b-4407-a91b-afd25b741f5f?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Eye drops, solution",
  "routes": [
    "Ocular use"
  ],
  "source": "hpra",
  "atc_all": [
    "S01HA02"
  ],
  "strength": null,
  "pa_number": "PA22584/002/001",
  "substances": [
    "Oxybuprocaine hydrochloride"
  ],
  "legal_basis": "Well-established use application (Article 10a of Directive No 2001/83/EC)",
  "market_info": "Marketed",
  "authorised_at": "27/01/2023",
  "dispensing_status": "Product subject to prescription which may not be renewed (A)",
  "registration_status": "AU",
  "supply_legal_status": "Supply through pharmacies only",
  "interchangeable_code": null
}

API reference MCP server Plans

See everything about oxybuprocaine.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it free Open in the console